University of Guelph   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Guelph ON Canada (1903)

Organization Overview

First Clinical Trial
2004
NCT02816125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Adjunct Professor | Alison Duncan | Jamie Burr | Research Ethics Officer, University of Guelph | The University of Guelph | University of Guelph | University of Guelph, Human Nutraceutical Research Unit

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 1)

Anemia, Iron-Deficiency (Phase 1)

Breast Neoplasms (Phase 3)

Disease (Phase 1)

Hemoglobinopathies (Phase 1)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 1)

Insulin Resistance (Phase 2)

Lipid Metabolism Disorders (Phase 1)

Marijuana Abuse (Phase 1)

Metabolic Diseases (Phase 1)

Metabolic Syndrome (Phase 3)

Muscle Weakness (Phase 3)

Nutrition Disorders (Phase 1)

Overnutrition (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial APIs: 31